SGEN Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 Dez 2023 @ 22:00):

Stats
Tagesvolumen	19.39M
Durchschnittsvolumen	1.63M
Marktkapitalisierung	43.15B
EPS	$0 ( 2024-04-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-57.19
ATR14	$1.424 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Baker Bros. Advisors Lp	Sell	42 977 301	Common Stock
2023-12-14	Baker Bros. Advisors Lp	Sell	8 750	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 44 783 214

Volumen Korrelation

Lang: 0.24 (neutral)

Kurz: 0.00 (neutral)

Signal:(82.918) Neutral

Seattle Genetics Inc Korrelation

10 Am meisten positiv korreliert
MLTX	0.927
BLPH	0.927
LGST	0.924
INTA	0.918
SJ	0.917
MOTNU	0.911
MORF	0.907
SVFC	0.907
PESI	0.903
DSEY	0.903

10 Am meisten negativ korreliert
ESSA	-0.937
BSRR	-0.937
FNCB	-0.936
SIRI	-0.934
APEI	-0.921
BRKL	-0.92
BLFY	-0.919
ONEM	-0.916
FLIC	-0.913
BCOW	-0.912

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Seattle Genetics Inc Korrelation - Währung/Rohstoff

-0.75
( moderate negative )

-0.80
( strong negative )

0.25
( neutral )

-0.81
( strong negative )

-0.03
( neutral )

0.78
( moderate )

Seattle Genetics Inc Finanzdaten

Annual	2022
Umsatz:	$1.96B
Bruttogewinn:	$1.55B (79.10 %)
EPS:	$-3.30

FY	2022
Umsatz:	$1.96B
Bruttogewinn:	$1.55B (79.10 %)
EPS:	$-3.30

FY	2021
Umsatz:	$1.57B
Bruttogewinn:	$1.26B (80.21 %)
EPS:	$-3.70

FY	2020
Umsatz:	$2.18B
Bruttogewinn:	$1.96B (89.99 %)
EPS:	$3.51

Financial Reports:

No articles found.

Seattle Genetics Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.